Last updated: September 16, 2026
In the UK, cannabis remains a Class B drug under the Misuse of Drugs Act 1971, meaning the possession, supply and cultivation for recreational purposes are all criminal offences carrying significant potential sentences.
Since November 2018, medical cannabis has been legal to prescribe under the unlicensed ‘specials’ framework. While there are no restrictions on what conditions medical cannabis can be prescribed for under this framework, only specialist doctors on the General Medical Council specialist register can prescribe.
Furthermore, the overwhelming majority of prescriptions are private and paid for by the patient. Prescriptions under the National Health Service are far less common and much more tightly controlled.
Although there have been six prime ministers and as many administrations since 2018, no meaningful legislative changes to either medical or adult-use cannabis policy have taken place over those eight years.
An incoming Advisory Council for the Misuse of Drugs (ACMD) review of the UK’s medical cannabis prescribing framework could recommend significant changes when it is published. However, the government has no obligation to implement its recommendations, and its track record suggests it is unlikely to in the near future.
How has UK cannabis law changed since 2018?
Medical cannabis is the only part of UK cannabis law that has actually moved. Adult-use cannabis, while occasionally the focus of media attention, has not been amended since 2009.
In January 2004, Tony Blair’s government reclassified cannabis from Class B to Class C on advice from the ACMD, judging it ‘harmful, but less harmful than other Class B drugs’, seeing police adopt a presumption against arrest for adult possession.
Five years later, in January 2009, Gordon Brown’s government reversed the decision and moved cannabis back to Class B, this time overruling the ACMD outright, which had recommended cannabis stay Class C, citing the growing dominance of higher-potency ‘skunk’ cannabis in the market and concerns about mental health risks and public perception.
It remains the clearest precedent for a UK government rejecting its own drugs advisory body’s recommendation on cannabis, one the London Drugs Commission‘s unheeded 2025 report has since echoed.
In May 2022, London mayor Sadiq Khan launched the London Drugs Commission, an independent review chaired by Lord Charlie Falconer QC and supported by UCL research, to examine whether cannabis law was fit for purpose.
Labour’s July 2024 general election win initially changed the tone rather than the substance, Sir Keir Starmer said as prime minister that he had ‘no intention’ of changing drug law, calling the government’s approach ‘settled and not really a subject of great debate’, even as parliamentary attention to cannabis roughly doubled in Labour’s first year, from 34 mentions to 57, with the framing shifting from law-and-order towards patient access. The first Westminster Hall debate on medical cannabis under the new government followed on January 30, 2025.
The London Drugs Commission’s report, ‘The Cannabis Conundrum’, was published on May 28, 2025, with 42 recommendations. Its central proposal was to remove cannabis from the Misuse of Drugs Act 1971 altogether and regulate it instead under the Psychoactive Substances Act 2016, in effect, decriminalising personal possession while keeping supply and cultivation criminal offences.
The Home Office’s response was immediate and blunt. The government had ‘no intention of reclassifying cannabis from a Class B substance’. That remains the position as of September 2026.
Medical cannabis legislation has similarly remained largely unchanged since 2018, despite the rapid growth of the private market.
The starting point was November 1, 2018, when cannabis-based products for medicinal use were rescheduled to Schedule 2 of the Misuse of Drugs Regulations 2001, making them prescribable by specialist doctors for the first time. The change followed the cases of Billy Caldwell and Alfie Dingley, two children with severe epilepsy whose treatment access became a national story.
From there, growth has been almost entirely on the private prescribing side. According to the latest public figures, prescription items dispensed in English community pharmacies rose from 282,979 in 2023 to 668,511 in 2024 (up 136%) to 1,701,064 in 2025 (up 154%), equating to a more than 6000-fold increase since 2019.
None of that growth has come through the NHS: the NHS’s own registry, launched in mid-2025, counts around 1,000 patients on the three licensed products (Sativex, Epidyolex and Nabilone), against 100,000-plus patients being treated privately.
The most recent efforts to force change through the parliamentary process came in September 2026. New Clause 116 to the Health Bill, tabled September 3, 2026 by Liberal Democrat MP Anna Sabine and 17 colleagues, sought a review and clinical trials into children’s access to medicinal cannabis on the NHS.
It was not called at the report stage, and the Bill moved to the House of Lords on September 8.
What does UK cannabis law actually say in 2026?
Recreational cannabis carries a maximum sentence of five years’ imprisonment for possession and up to 14 years for supply and production, under Class B of the Misuse of Drugs Act 1971.
There is no legal recreational market of any kind, including dispensaries, cannabis social clubs, home cultivation allowance or depenalised personal-use thresholds in national law.
In practice, enforcement varies. Several London boroughs have run drug diversion pilots since January 2022. Bexley, Greenwich and Lewisham direct under-25s caught in possession towards education or treatment rather than prosecution. This is diversion, not decriminalisation. Someone diverted is ‘not put through the criminal justice system, but they’re also not just let off the hook’ either, and the underlying offence has not changed.
Medical cannabis sits in a separate legal category. Cannabis-based products for medicinal use are Schedule 2 controlled drugs, prescribable only by specialist doctors on the General Medical Council specialist register, not GPs.
NHS prescribing remains almost entirely restricted to the three licensed products; unlicensed cannabis-based medicines are available on the NHS only in a handful of cases nationally. The market that has actually grown is private prescribing, mostly through telemedicine platforms, now covering what is estimated to be more than 100,000 patients and running on imported flower, 30,120 kg in 2025, more than half of it sourced from Canada.
CBD and hemp products fall under a third, separate regime entirely, governed by post-Brexit Novel Food rules rather than the Misuse of Drugs Act, and are not addressed further here.
What would have to change for cannabis to be legalised?
| Current legal position | London Drugs Commission recommendation | Government response | |
| Personal possession | Class B criminal offence, up to 5 years | Remove from Misuse of Drugs Act 1971; regulate under Psychoactive Substances Act 2016 | Rejected — ‘no intention of reclassifying’ |
| Supply and cultivation | Class B criminal offence, up to 14 years | Remains criminal under Commission’s proposal | Not applicable |
| Police search powers | Cannabis smell/suspicion can justify stop and search | Ban stop-and-search based solely on suspected cannabis possession | No commitment made |
| Criminal record impact | Cannabis possession convictions are disclosable | Make cannabis possession non-disclosable in criminal record checks | No commitment made |
| Medical access | Specialist-only prescribing; NHS access limited to ~1,000 patients | Fund further clinical research; improve police understanding of prescription law | ACMD review commissioned June 2025; NC116 not adopted (Sept 2026) |
Two distinct legislative routes exist, and neither is currently moving. Recreational reclassification would need either a statutory instrument backed by ACMD advice and the Home Secretary, or primary legislation, and the government explicitly closed off that route sin 2025.
The more active front is medical, with the ACMD’s ongoing review of the regulations underpinning the 2018 framework originally due to report by summer 2026, though it remains outstanding. This represents the nearest thing to a live process that could change prescribing law, even though it stops well short of recreational reform.
What are the commercial stakes?
The UK’s medical cannabis market alone is now estimated to be worth £297.9m in 2026, across 124,144 patients, according to Prohibition Partners’ latest figures. Flower imports reached 30,120kg in 2025, doubling year-on-year, alongside a 246% rise in THC extract imports to 395.5kg.
The illicit recreational market, meanwhile, is estimated at more than £3bn a year, and reform advocates have pointed to a potential £2bn in annual tax revenue were recreational use legalised and taxed, though these figures remain in the realm of advocacy modelling rather than government forecasting, since no legalisation proposal is currently on the table to cost.
FAQs
Is cannabis legal in the UK in 2026?
No. Recreational cannabis remains a Class B controlled drug under the Misuse of Drugs Act 1971. Medical cannabis has been legal in prescription-only form since November 2018.
Has the UK government said it will legalise cannabis?
No. The Home Office has stated explicitly that it has ‘no intention’ of reclassifying cannabis from a Class B substance, a position restated after London’s own commissioned review recommended decriminalisation in May 2025.
What did the London Drugs Commission recommend?
Its May 2025 report recommended removing cannabis from the Misuse of Drugs Act 1971 and regulating it instead under the Psychoactive Substances Act 2016, which would decriminalise personal possession while keeping supply and cultivation as criminal offences. The government rejected the core recommendation.
Are cannabis social clubs or home growing legal in the UK?
No. There is no legal allowance for home cultivation or membership-based cannabis clubs anywhere in UK law.
Does getting caught with cannabis always lead to prosecution?
Not always in practice. Some areas run diversion pilots directing under-25s towards education or treatment instead of prosecution, but this does not change the underlying legal status of the offence.
